Twist Bioscience puts antibody optimisation potential to use

Partnership to apply antibody optimisation platform to the targeting arm of a bispecific antibody

Twist Bioscience has collaborated with Pandion Therapeutics to apply its antibody optimisation platform to the targeting arm of a bispecific antibody. Pandion Therapeutics is a biotechnology platform company developing therapeutics to achieve localised immunomodulation to treat autoimmune and inflammatory disease.

“Twist Bioscience, through its Biopharma division, has a highly differentiated capability to optimise antibodies for many attributes including affinity, expression, solubility, half-life, immunogenicity, druggability and processability,” said Anthony Coyle, co-founder and CEO of Pandion.

Twist Bioscience’s focus appears to have been on antibodies of late, having just announced a collaboration with LakePharma to share antibody platform resources.

Now this initial project is on a key therapeutic target for new treatment options.

“By approaching autoimmune and inflammatory disease through antibody therapeutics acting locally at the disease site, Pandion is working to change the trajectory of treatment,” commented Emily M Leproust, CEO and co-founder of Twist Bioscience. “Using our state-of-the-art antibody optimisation platform, we look forward to partnering with Pandion to provide enhanced antibodies ideally suited to the human body to potentially improve patient outcomes.”

Companies